Skip to main content

Drug Interactions between Anoro Ellipta and methacholine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

methacholine vilanterol

Applies to: methacholine and Anoro Ellipta (umeclidinium / vilanterol)

ADJUST DOSING INTERVAL: Anticholinergics, beta-agonists, and theophylline may inhibit the bronchial airway response to methacholine. Methacholine is a cholinergic agonist that binds muscarinic receptors in bronchial smooth muscle, which leads to bronchoconstriction. Since patients with asthma exhibit greater sensitivity to induced bronchoconstriction than healthy subjects, methacholine is used to diagnose bronchial airway hyperreactivity in the absence of clinically apparent asthma. Bronchodilation caused by anticholinergics, beta-agonists, and theophylline may counteract methacholine-induced bronchoconstriction, possibly leading to diagnostic failure.

MANAGEMENT: Treatment with anticholinergics, beta-agonists, and theophylline should be interrupted before methacholine administration for the following durations:
--Short-acting anticholinergics (e.g., ipratropium): 12 hours
--Long-acting anticholinergics (e.g., tiotropium): At least 168 hours
--Short-acting beta-agonists (e.g., albuterol): 6 hours
--Long-acting beta-agonists (e.g., salmeterol): 36 hours (some authorities recommend 48 hours for ultra-long-acting beta-agonists [e.g., indacaterol, olodaterol, vilanterol])
--Oral theophylline: 12 to 48 hours

References

  1. (2020) "Product Information. Provocholine (methacholine)." Galen Ltd
  2. (2022) "Product Information. Provocholine (methacholine)." Methapharm Inc, SUPPL-26

Switch to consumer interaction data

Moderate

methacholine umeclidinium

Applies to: methacholine and Anoro Ellipta (umeclidinium / vilanterol)

ADJUST DOSING INTERVAL: Anticholinergics, beta-agonists, and theophylline may inhibit the bronchial airway response to methacholine. Methacholine is a cholinergic agonist that binds muscarinic receptors in bronchial smooth muscle, which leads to bronchoconstriction. Since patients with asthma exhibit greater sensitivity to induced bronchoconstriction than healthy subjects, methacholine is used to diagnose bronchial airway hyperreactivity in the absence of clinically apparent asthma. Bronchodilation caused by anticholinergics, beta-agonists, and theophylline may counteract methacholine-induced bronchoconstriction, possibly leading to diagnostic failure.

MANAGEMENT: Treatment with anticholinergics, beta-agonists, and theophylline should be interrupted before methacholine administration for the following durations:
--Short-acting anticholinergics (e.g., ipratropium): 12 hours
--Long-acting anticholinergics (e.g., tiotropium): At least 168 hours
--Short-acting beta-agonists (e.g., albuterol): 6 hours
--Long-acting beta-agonists (e.g., salmeterol): 36 hours (some authorities recommend 48 hours for ultra-long-acting beta-agonists [e.g., indacaterol, olodaterol, vilanterol])
--Oral theophylline: 12 to 48 hours

References

  1. (2020) "Product Information. Provocholine (methacholine)." Galen Ltd
  2. (2022) "Product Information. Provocholine (methacholine)." Methapharm Inc, SUPPL-26

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer